Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.